PortalPublikationenQuality of survival and growth in children and young adults ...

Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma

Standard

Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. / Kennedy, Colin; Bull, Kim; Chevignard, Mathilde; Culliford, David; Dörr, Helmuth G; Doz, François; Kortmann, Rolf-Dieter; Lannering, Birgitta; Massimino, Maura; Navajas Gutiérrez, Aurora; Rutkowski, Stefan; Spoudeas, Helen A; Calaminus, Gabriele; PNET4 study group of the Brain Tumour Group of The European branch of the International Society of Paediatric Oncology (SIOP-E).

in: INT J RADIAT ONCOL, Jahrgang 88, Nr. 2, 01.02.2014, S. 292-300.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kennedy, C, Bull, K, Chevignard, M, Culliford, D, Dörr, HG, Doz, F, Kortmann, R-D, Lannering, B, Massimino, M, Navajas Gutiérrez, A, Rutkowski, S, Spoudeas, HA, Calaminus, G & PNET4 study group of the Brain Tumour Group of The European branch of the International Society of Paediatric Oncology (SIOP-E) 2014, 'Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma', INT J RADIAT ONCOL, Jg. 88, Nr. 2, S. 292-300. https://doi.org/10.1016/j.ijrobp.2013.09.046

APA

Kennedy, C., Bull, K., Chevignard, M., Culliford, D., Dörr, H. G., Doz, F., Kortmann, R-D., Lannering, B., Massimino, M., Navajas Gutiérrez, A., Rutkowski, S., Spoudeas, H. A., Calaminus, G., & PNET4 study group of the Brain Tumour Group of The European branch of the International Society of Paediatric Oncology (SIOP-E) (2014). Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. INT J RADIAT ONCOL, 88(2), 292-300. https://doi.org/10.1016/j.ijrobp.2013.09.046

Vancouver

Kennedy C, Bull K, Chevignard M, Culliford D, Dörr HG, Doz F et al. Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. INT J RADIAT ONCOL. 2014 Feb 1;88(2):292-300. https://doi.org/10.1016/j.ijrobp.2013.09.046

Bibtex

@article{374806cfe5114a279f5baf64953672c5,
title = "Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma",
abstract = "PURPOSE: To compare quality of survival in {"}standard-risk{"} medulloblastoma after hyperfractionated radiation therapy of the central nervous system with that after standard radiation therapy, combined with a chemotherapy regimen common to both treatment arms, in the PNET4 randomised controlled trial.METHODS AND MATERIALS: Participants in the PNET4 trial and their parents/caregivers in 7 participating anonymized countries completed standardized questionnaires in their own language on executive function, health status, behavior, health-related quality of life, and medical, educational, employment, and social information. Pre- and postoperative neurologic status and serial heights and weights were also recorded.RESULTS: Data were provided by 151 of 244 eligible survivors (62%) at a median age at assessment of 15.2 years and median interval from diagnosis of 5.8 years. Compared with standard radiation therapy, hyperfractionated radiation therapy was associated with lower (ie, better) z-scores for executive function in all participants (mean intergroup difference 0.48 SDs, 95% confidence interval 0.16-0.81, P=.004), but health status, behavioral difficulties, and health-related quality of life z-scores were similar in the 2 treatment arms. Data on hearing impairment were equivocal. Hyperfractionated radiation therapy was also associated with greater decrement in height z-scores (mean intergroup difference 0.43 SDs, 95% confidence interval 0.10-0.76, P=.011).CONCLUSIONS: Hyperfractionated radiation therapy was associated with better executive function and worse growth but without accompanying change in health status, behavior, or quality of life.",
keywords = "Adolescent, Age Factors, Antineoplastic Combined Chemotherapy Protocols, Behavior, Cerebellar Neoplasms, Child, Child, Preschool, Combined Modality Therapy, Dose Fractionation, Employment, Europe, Executive Function, Female, Follow-Up Studies, Growth, Health Status, Hearing, Hormone Replacement Therapy, Humans, Male, Medulloblastoma, Outcome Assessment (Health Care), Quality of Life, Questionnaires, Survivors, Young Adult",
author = "Colin Kennedy and Kim Bull and Mathilde Chevignard and David Culliford and D{\"o}rr, {Helmuth G} and Fran{\c c}ois Doz and Rolf-Dieter Kortmann and Birgitta Lannering and Maura Massimino and {Navajas Guti{\'e}rrez}, Aurora and Stefan Rutkowski and Spoudeas, {Helen A} and Gabriele Calaminus and {PNET4 study group of the Brain Tumour Group of The European branch of the International Society of Paediatric Oncology (SIOP-E)}",
note = "Copyright {\textcopyright} 2014 Elsevier Inc. All rights reserved.",
year = "2014",
month = feb,
day = "1",
doi = "10.1016/j.ijrobp.2013.09.046",
language = "English",
volume = "88",
pages = "292--300",
journal = "INT J RADIAT ONCOL",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma

AU - Kennedy, Colin

AU - Bull, Kim

AU - Chevignard, Mathilde

AU - Culliford, David

AU - Dörr, Helmuth G

AU - Doz, François

AU - Kortmann, Rolf-Dieter

AU - Lannering, Birgitta

AU - Massimino, Maura

AU - Navajas Gutiérrez, Aurora

AU - Rutkowski, Stefan

AU - Spoudeas, Helen A

AU - Calaminus, Gabriele

AU - PNET4 study group of the Brain Tumour Group of The European branch of the International Society of Paediatric Oncology (SIOP-E)

N1 - Copyright © 2014 Elsevier Inc. All rights reserved.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - PURPOSE: To compare quality of survival in "standard-risk" medulloblastoma after hyperfractionated radiation therapy of the central nervous system with that after standard radiation therapy, combined with a chemotherapy regimen common to both treatment arms, in the PNET4 randomised controlled trial.METHODS AND MATERIALS: Participants in the PNET4 trial and their parents/caregivers in 7 participating anonymized countries completed standardized questionnaires in their own language on executive function, health status, behavior, health-related quality of life, and medical, educational, employment, and social information. Pre- and postoperative neurologic status and serial heights and weights were also recorded.RESULTS: Data were provided by 151 of 244 eligible survivors (62%) at a median age at assessment of 15.2 years and median interval from diagnosis of 5.8 years. Compared with standard radiation therapy, hyperfractionated radiation therapy was associated with lower (ie, better) z-scores for executive function in all participants (mean intergroup difference 0.48 SDs, 95% confidence interval 0.16-0.81, P=.004), but health status, behavioral difficulties, and health-related quality of life z-scores were similar in the 2 treatment arms. Data on hearing impairment were equivocal. Hyperfractionated radiation therapy was also associated with greater decrement in height z-scores (mean intergroup difference 0.43 SDs, 95% confidence interval 0.10-0.76, P=.011).CONCLUSIONS: Hyperfractionated radiation therapy was associated with better executive function and worse growth but without accompanying change in health status, behavior, or quality of life.

AB - PURPOSE: To compare quality of survival in "standard-risk" medulloblastoma after hyperfractionated radiation therapy of the central nervous system with that after standard radiation therapy, combined with a chemotherapy regimen common to both treatment arms, in the PNET4 randomised controlled trial.METHODS AND MATERIALS: Participants in the PNET4 trial and their parents/caregivers in 7 participating anonymized countries completed standardized questionnaires in their own language on executive function, health status, behavior, health-related quality of life, and medical, educational, employment, and social information. Pre- and postoperative neurologic status and serial heights and weights were also recorded.RESULTS: Data were provided by 151 of 244 eligible survivors (62%) at a median age at assessment of 15.2 years and median interval from diagnosis of 5.8 years. Compared with standard radiation therapy, hyperfractionated radiation therapy was associated with lower (ie, better) z-scores for executive function in all participants (mean intergroup difference 0.48 SDs, 95% confidence interval 0.16-0.81, P=.004), but health status, behavioral difficulties, and health-related quality of life z-scores were similar in the 2 treatment arms. Data on hearing impairment were equivocal. Hyperfractionated radiation therapy was also associated with greater decrement in height z-scores (mean intergroup difference 0.43 SDs, 95% confidence interval 0.10-0.76, P=.011).CONCLUSIONS: Hyperfractionated radiation therapy was associated with better executive function and worse growth but without accompanying change in health status, behavior, or quality of life.

KW - Adolescent

KW - Age Factors

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Behavior

KW - Cerebellar Neoplasms

KW - Child

KW - Child, Preschool

KW - Combined Modality Therapy

KW - Dose Fractionation

KW - Employment

KW - Europe

KW - Executive Function

KW - Female

KW - Follow-Up Studies

KW - Growth

KW - Health Status

KW - Hearing

KW - Hormone Replacement Therapy

KW - Humans

KW - Male

KW - Medulloblastoma

KW - Outcome Assessment (Health Care)

KW - Quality of Life

KW - Questionnaires

KW - Survivors

KW - Young Adult

U2 - 10.1016/j.ijrobp.2013.09.046

DO - 10.1016/j.ijrobp.2013.09.046

M3 - SCORING: Journal article

C2 - 24239386

VL - 88

SP - 292

EP - 300

JO - INT J RADIAT ONCOL

JF - INT J RADIAT ONCOL

SN - 0360-3016

IS - 2

ER -